Dietary treatment for familial hypercholesterolaemia

Shafiq, Nusrat; Singh, Meenu; Kaur, Sharonjeet; Khosla, Pratibha; Malhotra, Samir

doi:10.1002/14651858.cd001918.pub2

Cited by 42 publications

(44 citation statements)

References 350 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although FO is a well-known TG-lowering agent, we and others have shown that it also determine whether Indo, an isoform-nonspecifi c COXIB, inhibits COX activity in our experimental condition, we determined the levels of TXs and PGs. We found that the levels of the AA-derived 2-series eicosanoids, such as TXB 2 and PGE 2 , were signifi cantly reduced in the liver of mice that received FO or Indo individually or in combination ( P < 0.001) ( Fig. 8A, D ).…”

Section: Discussionmentioning

confidence: 92%

“…On the other hand, the fatty acid ␤ -oxidation measured using [1][2][3][4][5][6][7][8][9][10][11][12][13][14] C]palmitic acid is not altered in these mice. However, in vivo peroxisomal metabolism of fatty acids leads to chain shortening but not to complete fatty acid oxidation.…”

Section: Discussionmentioning

confidence: 93%

“…Fatty acid oxidation was measured in whole liver homogenates by measuring and summing 14 CO 2 production and 14 C-labeled acid-soluble metabolites from the oxidation of [1][2][3][4][5][6][7][8][9][10][11][12][13][14] C]palmitic acid as previously described (22)(23)(24).…”

Section: Measures Of Fatty Acid Oxidationmentioning

confidence: 99%

“…TXB 2 and PGE 2 are considered to be derived mainly from AA via COX-1 and COX-2 activities, respectively. To Western blot analysis of nuclear extracts revealed that the activities of PPAR ␣ showed only a trend toward an increase in FO-and FO + Indo-treated mice.…”

Section: Effect Of Dietary Fo In the Presence Or Absence Of Indo On Tmentioning

confidence: 99%

See 3 more Smart Citations

Fish oil and indomethacin in combination potently reduce dyslipidemia and hepatic steatosis in LDLR −/− mice

Ganesan

Milne

Webb

et al. 2012

Journal of Lipid Research

View full text Add to dashboard Cite

This article is available online at http://www.jlr.org Dyslipidemia, which is characterized by elevated cholesterol or triglycerides, is a major risk factor for coronary heart disease (as reviewed in Ref. 1 ). One of the most studied forms of dyslipidemia is familial hypercholesterolemia (FH) caused by genetic factors. Although homozygous FH is a rare condition, heterozygous FH occurs in approximately 1 in 500 people and can cause premature atherosclerotic disease (as reviewed in Ref. 2 ). Combination therapy is commonly used in clinical practice to improve hypercholesterolemia. The most commonly used combination therapy consists of statins with fi brates or niacin. However, this combination has limited additive effect on LDL cholesterol levels. Moreover, the poor tolerance of niacin and the statin-induced side effects (e.g., muscle toxicity) limit the use of this combination (as reviewed in Refs. 3 and 4 ). In addition to dyslipidemia, infl ammation by itself can lead to increased risk of coronary heart disease. Therefore, a therapeutic regimen that has the potential to reduce dyslipidemia and infl ammation would be more benefi cial in reducing cardiovascular events than treatments aimed at improving dyslipidemia alone.Fish oil (FO) containing n-3 polyunsaturated fatty acids such as eicosapentaenoic acid and docosahexaenoic acid

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 93%

Section: Measures Of Fatty Acid Oxidationmentioning

confidence: 99%

Section: Effect Of Dietary Fo In the Presence Or Absence Of Indo On Tmentioning

confidence: 99%

See 2 more Smart Citations

Fish oil and indomethacin in combination potently reduce dyslipidemia and hepatic steatosis in LDLR −/− mice

Ganesan

Milne

Webb

et al. 2012

Journal of Lipid Research

View full text Add to dashboard Cite

show abstract

“…16 Modification of the baseline lifestyle including smoking cessation, physical activity and diet to reduce LDL-C, containing less than 7% saturated fat, less than 1% trans fats, and less than 200 mg of cholesterol per day but rich in Omega-3 fatty-acids should be encouraged, though the LDL-C lowering effect might be modest (10% reduction). 17 Statin therapy is the drug treatment with primary priority.…”

Section: Will Disease Management Be Influenced By the Results Of A Genmentioning

confidence: 99%